.jpg?format=webp&width=780)
The study investigates early salvage radiation therapy's efficacy for low-risk PSA recurrence post-radical prostatectomy. Primary endpoint: 3-year event-free survival, including PSA recurrence, metastatic evidence, or salvage treatments. Secondary endpoints analyze patient-reported outcomes, treatment patterns, perceptions, and cost-effectiveness. Eligible participants exhibit PSA levels of 0.2-0.5ng/mL, low risk as per EAU criteria, with no recurrent cancer on PSMA-PET/CT.
Like
Save
Share